Cargando…

Therapeutic landscape in mutational triple negative breast cancer

Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of both the germline and somatic alterations in TNBC, which is staggeringly different from other breast cancer subtypes. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Yaqin, Jin, Juan, Ji, Wenfei, Guan, Xiaoxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046102/ https://www.ncbi.nlm.nih.gov/pubmed/30007403 http://dx.doi.org/10.1186/s12943-018-0850-9

Ejemplares similares

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Jin, Juan, et al.
Publicado: (2018)

The long non‐coding RNA landscape in triple‐negative breast cancer
por: Zhang, Wenwen, et al.
Publicado: (2020)

The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
por: Luo, Jiayan, et al.
Publicado: (2016)

Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
por: Mehanna, Joe, et al.
Publicado: (2019)

Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes
por: Diana, Anna, et al.
Publicado: (2020)

Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

Analysis of different HER‐2 mutations in breast cancer progression and drug resistance
por: Sun, Zijia, et al.
Publicado: (2015)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023)

Evaluation of Breast Cancer Stem Cells and Intratumor Stemness Heterogeneity in Triple-negative Breast Cancer as Prognostic Factors
por: Yang, Fang, et al.
Publicado: (2016)

Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
por: Ribeiro, Rita, et al.
Publicado: (2022)

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
por: Hossain, Fokhrul, et al.
Publicado: (2021)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Novel therapeutic strategies for patients with triple-negative breast cancer
por: Zhang, Jun-Fei, et al.
Publicado: (2016)

Novel therapeutic strategies in the treatment of triple-negative breast cancer
por: Oualla, Karima, et al.
Publicado: (2017)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Pathogenesis and Potential Therapeutic Targets for Triple-Negative Breast Cancer
por: Li, Chia-Jung, et al.
Publicado: (2021)

Recent advances in therapeutic strategies for triple-negative breast cancer
por: Li, Yun, et al.
Publicado: (2022)

Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib
por: Ji, Wenfei, et al.
Publicado: (2019)

The pathological and clinical landscape of refractory metastatic triple negative breast cancer: a narrative review
por: Jiang, Meng-Ping, et al.
Publicado: (2022)

SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer
por: Tang, Lin, et al.
Publicado: (2020)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

Current Therapeutic Strategies for Metastatic Triple-Negative Breast Cancer: From Pharmacists’ Perspective
por: Li, Shuanghe, et al.
Publicado: (2022)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery
por: van der Noord, Vera E., et al.
Publicado: (2022)

The Potential Role of Nanotechnology in Therapeutic Approaches for Triple Negative Breast Cancer
por: Johnson, Rebecca, et al.
Publicado: (2013)

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer
por: Xiao, Yan, et al.
Publicado: (2022)

Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential
por: McHenry, Peter R., et al.
Publicado: (2023)

Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Munkácsy, Gyöngyi, et al.
Publicado: (2023)

Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
por: Zhang, Zhiying, et al.
Publicado: (2023)

The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer
por: Guo, Yan, et al.
Publicado: (2018)

Deconvolution of the Genomic and Epigenomic Interaction Landscape of Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2019)

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
por: Hu, Shaojun, et al.
Publicado: (2021)

Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022)

c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis
por: Ji, Wenfei, et al.
Publicado: (2020)

Immune-related biomarkers in triple-negative breast cancer
por: Zhang, Juan, et al.
Publicado: (2021)

Immunotherapeutic interventions of Triple Negative Breast Cancer
por: Li, Zehuan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c17hdaoa1p23br42d047k7iegk